Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome-Reference-Cited by-同舟云学术

Perioperative inhibition of β-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome

Published:2018-10 Issue: Volume:73 Page:294-309
ISSN:0889-1591
Container-title:Brain, Behavior, and Immunity
language:en
Short-container-title:Brain, Behavior, and Immunity

Author:

Haldar Rita,Shaashua Lee,Lavon Hagar,Lyons Yasmin A.,Zmora Oded,Sharon Eran,Birnbaum Yehudit,Allweis Tanir,Sood Anil K.,Barshack Iris,Cole Steve,Ben-Eliyahu Shamgar

Funder

National Cancer Institute

Israel Science Foundation

National Institutes of Health/National Institute on Aging

Publisher

Elsevier BV

Subject

Behavioral Neuroscience,Endocrine and Autonomic Systems,Immunology

Reference134 articles.

1. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity;Aigner;Oncogene,2007

2. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF);Akira;FASEB J.,1990

3. Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival;Albuquerque;Eur. J. Surg. Oncol.,1995